This is specifically reflected in the present study, by the confirmation of a strong relationship of ERβ1 with Ki67 in ERα-negative tumours, such that it seems likely that the addition of an ERβ1 antagonist could be a potentially useful therapy in specific subsets of breast cancer patients in a clinical setting. Here, MKI67 is linked to neoplasm.